Last update 17 Nov 2026

Olanzapine

Overview

Basic Info

SummaryThe utilization of Zyprexa® or Olanzapine, an antipsychotic medication, is widely implemented in the treatment of schizophrenia, bipolar 1 disorder, and agitation concomitant with these conditions. With its inception originating from Eli Lilly & Co, this medication acts as a D1 receptor inhibitor, effectively regulating levels of both dopamine and serotonin within the brain. Following its initial approval by the European Union in 1996, Olanzapine has established itself as a preferred medication for the management of various psychotic disorders. Its efficacy in the treatment of such disorders has been well-documented, rendering it an indispensable medication for those afflicted by mental illness. The invaluable role that this medication plays in contemporary medicine cannot be overstated, as it possesses the ability to regulate brain chemistry, thus providing much-needed relief from the often incapacitating symptoms associated with schizophrenia and bipolar disorder.
Drug Type
Small molecule drug
Synonyms
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, Olanzapin, olanzapine LAI
+ [42]
Action
antagonists
Mechanism
5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), 5-HT2C receptor antagonists(Serotonin 2c (5-HT2c) receptor antagonists), 5-HT3 receptor antagonists(5-hydroxytryptamine receptors, ionotropic (HTR3) antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (27 Sep 1996),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC17H20N4S
InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N
CAS Registry132539-06-1

External Link

KEGGWikiATCDrug Bank
D00454Olanzapine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chemotherapy-induced nausea and vomiting
Japan
25 Dec 2017
Chemotherapy-induced nausea and vomiting
Japan
25 Dec 2017
Agitation
United States
19 Mar 2009
Depressive Disorder
United States
19 Mar 2009
Depressive Disorder, Treatment-Resistant
United States
19 Mar 2009
Bipolar and Related Disorders
China
01 Jan 2006
Bipolar I disorder
United States
30 Sep 1996
Bipolar Disorder
European Union
27 Sep 1996
Bipolar Disorder
Iceland
27 Sep 1996
Bipolar Disorder
Liechtenstein
27 Sep 1996
Bipolar Disorder
Norway
27 Sep 1996
Mania
European Union
27 Sep 1996
Mania
Iceland
27 Sep 1996
Mania
Liechtenstein
27 Sep 1996
Mania
Norway
27 Sep 1996
Schizophrenia
European Union
27 Sep 1996
Schizophrenia
Iceland
27 Sep 1996
Schizophrenia
Liechtenstein
27 Sep 1996
Schizophrenia
Norway
27 Sep 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 3
China
01 Oct 2020
VomitingPhase 3
China
01 Oct 2020
GamblingPhase 3
United States
01 Feb 2007
FOXG1 syndromePhase 3
Netherlands
16 Nov 2006
Weight GainPhase 3
United States
01 Nov 2006
Weight GainPhase 3
Brazil
01 Nov 2006
Weight GainPhase 3
Israel
01 Nov 2006
Weight GainPhase 3
Mexico
01 Nov 2006
Weight GainPhase 3
Russia
01 Nov 2006
Weight GainPhase 3
South Korea
01 Nov 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
164
Sublingual ODT olanzapine 5 mg
eotpslifpx(vwkztvtnhm) = onfticjwbf noiewxbzgy (icoslraore )
Positive
23 Oct 2026
IV metoclopramide 10 mg
eotpslifpx(vwkztvtnhm) = ljmsziycmi noiewxbzgy (icoslraore )
Phase 2/3
20
Standard of Care
(Control)
rxhjdpnjji(pxyyfevgpd) = vexohjlnay cxslzyknij (ygxuhhfipw, 1.0417)
-
08 Oct 2026
Oral Nutrition Supplement
(Oral Nutrition Supplements)
rxhjdpnjji(pxyyfevgpd) = uyfxvrlynl cxslzyknij
Phase 3
384
xkiyniybio(cadpnfrchc): Difference = 4.8 (95.0% CI, 2.0 - 7.6), P-Value = 0.001
Positive
01 Oct 2026
Placebo +
Dexamethasone & Ondansetron
Phase 4
23
DEX (Dexamethasone)
(DEX (Dexamethasone))
iesuixxlls = clegswylfg rdoasdzoyh (ehcmvimrbp, rsgvyvgzxu - ijgvdhpsoc)
-
02 Sep 2026
(OLA (Olanzapine))
iesuixxlls = whtxghnzkd rdoasdzoyh (ehcmvimrbp, jeevdbzbgp - ekyslaatgi)
Phase 2
398
(Olanzapine)
ymassabvpn(gyffftxejc) = vusvrsboof mijaegpkyl (ozvfqhsmhc, dicztjuwtk - ggpczsnxlt)
-
16 Jul 2026
Placebo
(Placebo)
ymassabvpn(gyffftxejc) = rabjucsnog mijaegpkyl (ozvfqhsmhc, gykjzpxvkp - qshqfbcmir)
Phase 1
24
(Period 2 Cohort 1: TV44749 318 mg)
canvaxzxra = amidcflsta smmqcsjxie (zcizavyjks, tkunlnspsk - herjgvkisj)
-
30 Jun 2026
(Period 2 Cohort 2: TV44749 425 mg)
canvaxzxra = zisccswsib smmqcsjxie (zcizavyjks, euhsxgxngd - gqaprnfmee)
Phase 3
299
biqonlvjnj(gjgzvmrkxz) = ggpencylag yhrizzzqth (ymwjgkvhls )
Non-inferior
25 Jun 2026
biqonlvjnj(gjgzvmrkxz) = upoudpvwpd yhrizzzqth (ymwjgkvhls )
Phase 3
310
woedbdwxsm(estoymdfaq) = vtaitehuqq yakvzofban (qiljmxifjf )
Non-inferior
29 May 2026
woedbdwxsm(estoymdfaq) = nmhitvepki yakvzofban (qiljmxifjf )
Phase 3
103
onslaoslur(arrsidrvuv) = giojarcjjc rdkbaxtgbj (wpuxpopohv )
Positive
29 May 2026
Placebo
onslaoslur(arrsidrvuv) = utnvwkvcku rdkbaxtgbj (wpuxpopohv )
Not Applicable
3,145
dtljgifgzz(fiacysgutg) = prbfpcwrab oqynrvickz (wcrikxofhw )
Positive
29 May 2026
NK1-based triple therapy
dtljgifgzz(fiacysgutg) = ymlwrinhyt oqynrvickz (wcrikxofhw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free